NDA 219685 · Genzyme Corp
Wayrilz
Rilzabrutinib · Oral · Kinase Inhibitor
NovelOrphanCDER novel approval, Aug 29, 2025: To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids
Last checked: Nov 19, 2026Latest source record: Aug 29, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Aug 29, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
23
8 Phase 3, 7 recruiting
FAERS reports
564
113 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 26, 2025.
WAYRILZ is indicated for the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. WAYRILZ is a kinase inhibitor indicated for the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. ( 1 )
Mechanism: Rilzabrutinib is a small-molecule, covalent, reversible kinase inhibitor targeting Bruton's tyrosine kinase (BTK). Rilzabrutinib mediates its therapeutic effect in ITP through immune modulation including 1) inhibition of B cell activation, and 2) interruption of antibody-coated cell phagocytosis by Fcγ receptor (FcγR) in spleen and liver. In vitro , rilzabrutinib reduced autoantibody signaling mediated through the FcγR pathway, blocked B cell signaling, and decreased autoantibody generation through effects on B cell activation.
Therapeutic areas: Oncology · Hematology and blood cancers · Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- WAYRILZ · RILZABRUTINIB 400MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rilzabrutinib" as an intervention, any sponsor and status, largest first.
- Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)Pivotal-lookingCompleted
Principia Biopharma, a Sanofi CompanyIndustry
NCT04562766 · 232 participants · Start Dec 14, 2020 · Primary completion Jan 15, 2025
Drug: Rilzabrutinib; Placebo · For: Immune Thrombocytopenia
Sites: Los Angeles, California; San Francisco, California; Torrance, California · 155 sites in all
- Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe AsthmaPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT05104892 · 196 participants · Start Dec 12, 2021 · Primary completion Feb 6, 2024
Drug: Rilzabrutinib; placebo · For: Asthma
Sites: Berazategui, Argentina; CABA, Argentina; Buenos Aires, Argentina · 51 sites in all
- The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT06975865 · 192 participants (planned) · Start Aug 12, 2025 · Primary completion Jul 23, 2027
Drug: Rilzabrutinib; Placebo · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Clovis, California · 64 sites in all
- Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 AntihistaminePivotal-lookingCompleted
SanofiSanofi (SNY)
NCT05107115 · 160 participants · Start Nov 24, 2021 · Primary completion Jul 19, 2023
Drug: rilzabrutinib; placebo · For: Chronic Spontaneous Urticaria
Sites: CABA, Argentina; Rosario, Argentina; Buenos Aires, Argentina · 128 sites in all
- A Study of PRN1008 in Patients With PemphigusPivotal-lookingTerminated
Principia Biopharma, a Sanofi CompanyIndustry
NCT03762265 · 131 participants · Start Jan 8, 2019 · Primary completion Jul 30, 2021
Drug: Rilzabrutinib; Placebo · For: Pemphigus
Sites: Boca Raton, Florida; Coral Gables, Florida; Atlanta, Georgia · 88 sites in all
- Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic DermatitisPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT05018806 · 124 participants · Start Sep 9, 2021 · Primary completion Jun 23, 2023
Drug: Placebo; Rilzabrutinib · For: Atopic Dermatitis
Sites: Northridge, California; Colorado Springs, Colorado; Miami, Florida · 31 sites in all
- A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related DiseasePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07190196 · 124 participants (planned) · Start Sep 26, 2025 · Primary completion Jun 28, 2028
Drug: Rilzabrutinib; Placebo and 1 more · For: Immunoglobulin G4 Related Disease
Sites: Fontana, California; Sacramento, California; San Jose, California · 95 sites in all
- Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and TolerabilityPivotal-lookingNot yet recruiting
SanofiSanofi (SNY)
NCT07923305 · 96 participants (planned) · Start Nov 9, 2026 · Primary completion May 10, 2035
Drug: rilzabrutinib; placebo · For: Immunodeficiency Common Variable
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- platelet count decreased143
- diarrhoea142
- nausea105
- drug ineffective92
- headache52
- fatigue50
- product use in unapproved indication47
- abdominal discomfort39
- vomiting29
- dizziness23
- arthralgia21
- asthenia21
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 2 |
| 2025 | 110 |
| 2026 | 452 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.
Kuter DJ, Ghanima W, Cooper N, et al. · Blood 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
Kuter DJ, Efraim M, Mayer J, et al. · N Engl J Med 2022 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia.
Kuter DJ, Mayer J, Efraim M, et al. · Blood Adv 2024 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study.
Murrell DF, Caux F, Patsatsi A, et al. · J Invest Dermatol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial.
Giménez-Arnau A, Ferrucci S, Ben-Shoshan M, et al. · JAMA Dermatol 2025 · Clinical Trial, Phase II, Randomized Controlled Trial
- Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study.
Cooper N, Jansen AJG, Bird R, et al. · Am J Hematol 2025 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.